MED's Trilivy launch marks a major metabolic-health shift, backed by a 10-year roadmap and growing GLP-1 market focus.
Medifast (MED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MED is reshaping its coach network around Executive Directors as productivity rises despite a sharp decline in active earning coaches.
| Personal Care Products Industry | Consumer Staples Sector | Nicholas Johnson CEO | XFRA Exchange | 58470H101 CUSIP |
| US Country | 380 Employees | 7 Nov 2023 Last Dividend | - Last Split | 31 Dec 1993 IPO Date |
Medifast, Inc. operates as a diversified health and wellness company, focused on manufacturing and selling a broad range of weight loss, weight management, and healthy living products. The company, with a strong foundation laid in 1980, runs its operations primarily across the United States and the Asia-Pacific regions. Strengthened by a network of subsidiaries, Medifast is known for its innovative approach to health and wellness products, promoting healthier living standards through its dedicated offerings. The strategic headquarters situated in Baltimore, Maryland, acts as a central hub for orchestrating its vast array of services and pushing the envelope in the health sector. Medifast’s approach to market its offerings extends beyond traditional point-of-sale transactions, incorporating a robust e-commerce platform that widens its reach and accessibility to a global consumer base.
Medifast, Inc. has developed a comprehensive product line under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names, catering to diverse consumer needs for weight loss, weight management, and healthy lifestyle needs: